Market research
CDG.F Acorda Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14M
- P/E ratio
- 0.97
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.37
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 14M
- P/E ratio
- 0.97
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.37
About
About Acorda Therapeutics, Inc
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CDG.F discussion.
5 years, 5 months ago
Acorda Therapeutics, Inc is currently in a long term uptrend where the price is trading 18.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.2.
Acorda Therapeutics, Inc's total revenue rose by 11.2% to $53M since the same quarter in the previous year.
Its net income has increased by 102.8% to $7M since the same quarter in the previous year.
Finally, its free cash flow grew by 93.3% to $-3M since the same quarter in the previous year.
Based on the above factors, Acorda Therapeutics, Inc gets an overall score of 5/5.